15 Most Promising Mid-Cap Healthcare Stocks Under $50

Page 9 of 15

7. Alkermes plc (NASDAQ:ALKS)

Sector/Industry: Healthcare (Drug Manufacturers – Specialty & Generic)

Share Price: $28.45

Potential Upside: 62.3%

Number of Hedge Fund Holders: 46

Alkermes plc (NASDAQ:ALKS) is one of the most promising mid-cap healthcare stocks under $50.

At the close of play on December 19, the consensus ratings remain bullish for Alkermes plc (NASDAQ:ALKS). The stock has been covered by 15 analysts, of which 11 assigned it Buy ratings and the remaining 4 were Holds. As per analyst estimates, the forecasted median 1-year price target for the stock is $46.17 a share, resulting in 62.3% upside potential at the prevailing prices.

On December 3, the company Chairman and CEO, Richard Pops, presented at the Evercore 8th Annual Healthcare Conference. He described 2025 as a truly transformational year for the business. Apart from positive NT1 and NT2 data, he also spoke about the company’s aggressive pursuits within the hypersomnolence market. Alkermes (NASDAQ:ALKS) plans to acquire Avadel, a profitable company with a circa $275 million topline. Pops linked this strategic acquisition with their planned launch of alixorexton, an oral drug for treating complex sleep disorders.

On December 5, Piper Sandler analyst David Amsellem also reaffirmed his bullish view of Alkermes (NASDAQ:ALKS). He gave a Buy call for the stock with a price target of $45. As per his estimates, the stock currently offers more than 58% upside potential to investors.

Alkermes (NASDAQ:ALKS) is a biopharmaceutical company that develops and commercializes innovative medicines to address neurological disorders. The company leverages its proprietary technologies for formulations that cater to individuals with psychiatric conditions. They also directly purchase active drugs from third parties.

Page 9 of 15